Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.54 |
| ▸ | RARB | P10826 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27530408 | 0.90 | POLB (0.66) | POLBTDP1MEN1KMT2AMMP1 | |
| SCHEMBL11676473 | 0.84 | NAAA (0.61) | POLBTDP1MEN1KMT2AMMP1 | |
| SCHEMBL11677404 | 0.84 | NAAA (0.61) | POLBTDP1MEN1KMT2AMMP1 | |
| SCHEMBL27623142 | 0.84 | NAAA (0.61) | POLBTDP1MEN1KMT2AMMP1 | |
| SCHEMBL11675750 | 0.82 | TDP1 (0.59) | POLBTDP1MEN1KMT2ATP53 | |
| SCHEMBL11677909 | 0.82 | MEN1 (0.79) | POLBTDP1MEN1KMT2AMMP1 | |
| SCHEMBL8947350 | 0.81 | MMP1 (0.72) | POLBTDP1MEN1KMT2AMMP1 | |
| Terephthalic Acid SCHEMBL28237282 | 0.80 | TSHR (0.63) | POLBTDP1TP53TSHRHTT | |
| Terephthalic Acid SCHEMBL23910547 | 0.80 | TSHR (0.63) | POLBTDP1TP53TSHRHTT | |
| SCHEMBL24224262 | 0.79 | KMT2A (0.59) | POLBTDP1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, LIPA, ACSL3 | POLB 1643/4885TDP1 4278/4885MEN1 2765/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | POLB 1446/4885TDP1 4230/4885MEN1 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.